Scarica l'app Stockscreener
71.11
4.40%
3.00
Pre-mercato:
70.14
-0.97
-1.36%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$68.11
Aprire:
$69
Volume 24 ore:
1.01M
Relative Volume:
0.92
Capitalizzazione di mercato:
$1.99B
Reddito:
$90.12M
Utile/perdita netta:
$-276.06M
Rapporto P/E:
-48.71
EPS:
-1.46
Flusso di cassa netto:
$-193.47M
1 W Prestazione:
+1.05%
1M Prestazione:
+88.92%
6M Prestazione:
+97.64%
1 anno Prestazione:
+8,327%
Intervallo 1D:
$68.00
$72.98
Intervallo di 1 settimana:
$64.50
$72.98
Portata 52W:
$0.432
$75.67
Nektar Therapeutics Stock (NKTR) Company Profile
Nome
Nektar Therapeutics
Settore
Industria
Telefono
(415) 482-5300
Indirizzo
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
71.11 | 1.91B | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-10 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-11-26 | Iniziato | Citigroup | Buy |
| 2025-06-24 | Reiterato | BTIG Research | Buy |
| 2025-06-24 | Reiterato | H.C. Wainwright | Buy |
| 2025-04-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-03-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-01-08 | Iniziato | B. Riley Securities | Buy |
| 2024-12-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-04 | Iniziato | Piper Sandler | Overweight |
| 2024-09-30 | Ripresa | BTIG Research | Buy |
| 2024-06-28 | Iniziato | Rodman & Renshaw | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Underweight |
| 2023-11-09 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | Aggiornamento | Jefferies | Underperform → Hold |
| 2023-02-24 | Downgrade | Jefferies | Hold → Underperform |
| 2022-08-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Ripresa | Jefferies | Hold |
| 2022-04-18 | Downgrade | Goldman | Neutral → Sell |
| 2022-03-15 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-15 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2022-03-14 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Downgrade | Stifel | Buy → Hold |
| 2022-03-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Iniziato | BofA Securities | Neutral |
| 2021-06-28 | Aggiornamento | Stifel | Hold → Buy |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-02-22 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-09-14 | Iniziato | JP Morgan | Neutral |
| 2020-06-10 | Downgrade | CFRA | Hold → Sell |
| 2020-05-12 | Reiterato | H.C. Wainwright | Neutral |
| 2020-04-22 | Iniziato | The Benchmark Company | Buy |
| 2020-03-30 | Aggiornamento | Goldman | Sell → Neutral |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-02-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-08 | Downgrade | Goldman | Buy → Sell |
| 2019-08-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Downgrade | Jefferies | Buy → Hold |
| 2019-08-09 | Downgrade | Mizuho | Buy → Neutral |
| 2019-03-15 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-06-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Reiterato | H.C. Wainwright | Buy |
| 2018-04-20 | Iniziato | Seaport Global Securities | Buy |
| 2018-04-13 | Ripresa | Piper Jaffray | Overweight |
| 2018-04-06 | Reiterato | Mizuho | Buy |
| 2018-04-02 | Ripresa | H.C. Wainwright | Buy |
Mostra tutto
Nektar Therapeutics Borsa (NKTR) Ultime notizie
Nektar Therapeutics at TD Cowen Conference: Immunology Focus - Investing.com Nigeria
Nektar Therapeutics at TD Cowen Conference: Immunology Focus By Investing.com - Investing.com UK
Nektar Therapeutics (HAM:ITH0) Selling and Marketing Expens - GuruFocus
Assessing Nektar Therapeutics (NKTR) Valuation After New Multiple Sclerosis Collaboration With UCSF - Yahoo Finance
Does Nektar (NKTR)–UCSF MS Collaboration Hint At A Broader Neuroscience Pivot For The Company? - Yahoo Finance
Assessing Nektar Therapeutics (NKTR) Valuation After Recent Share Price Momentum And Undervaluation Narrative - simplywall.st
BTIG Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $151 - 富途牛牛
Erste Asset Management GmbH Takes $1 Million Position in Nektar Therapeutics $NKTR - MarketBeat
Nektar Therapeutics (HAM:ITH0) Accounts Payable : €15.56 Mil (As of Sep. 2025) - GuruFocus
Nektar Therapeutics (HAM:ITH0) Inventories, Work In Process : €0.00 Mil (As of Sep. 2025) - GuruFocus
Nektar Therapeutics (HAM:ITH0) Short-Term Capital Lease Obl - GuruFocus
Nektar Therapeutics (HAM:ITH0) Cash Flow from Others : €-60.04 Mil (TTM As of Sep. 2025) - GuruFocus
Nektar Therapeutics (HAM:ITH0) Stock Price, Trades & News - GuruFocus
Nektar Therapeutics to Participate in Two Investor Conferences in March - Sahm
Nektar Therapeutics Stock Historical Valuations - GuruFocus
Nektar Therapeutics (HAM:ITH0) Return-on-Tangible-Equity : -466.82% (As of Sep. 2025) - GuruFocus
Nektar Therapeutics (HAM:ITH0) Cyclically Adjusted Book per Share : €0.00 (As of Sep. 2025) - GuruFocus
Nektar Therapeutics (HAM:ITH0) Capex-to-Operating-Cash-Flow : 0.00 (As of Sep. 2025) - GuruFocus
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets - Finviz
United StatesGoodwin Advises Nektar Therapeutics On Its $460 Million Public Offering, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares - Mondaq
Nektar Therapeutics sets March 12 call on 2025 financials - Stock Titan
Nektar Therapeutics MS Collaboration Adds New Angle To Volatile Stock Story - simplywall.st
Wall Street Analysts Think Nektar (NKTR) Could Surge 89.8%: Read This Before Placing a Bet - Finviz
Nektar Therapeutics (NKTR) Price Target Increased by 13.48% to 132.45 - Nasdaq
Nektar Therapeutics to Participate in Two Investor Conferences i - GuruFocus
Wall Street experts predict that Nektar (NKTR) may climb by 89.8%: Consider this information before making an investment decision - Bitget
Back-to-back investor conferences send Nektar to Boston and Miami - Stock Titan
Nektar Therapeutics (NASDAQ:NKTR) Sets New 52-Week HighTime to Buy? - MarketBeat
Nektar Therapeutics stock hits 52-week high at 75.19 USD By Investing.com - Investing.com India
Nektar Therapeutics’ (NKTR) “Buy” Rating Reaffirmed at B. Riley Financial - Defense World
A Look At Nektar Therapeutics (NKTR) Valuation After New UCSF Multiple Sclerosis Collaboration - simplywall.st
Nektar Therapeutics (NKTR) Receives Positive Analyst Rating Upgr - GuruFocus
B. Riley Securities Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Raises Target Price to $150 - 富途牛牛
Nektar Therapeutics stock hits 52-week high at 75.19 USD - Investing.com
B. Riley Raises Price Target on Nektar Therapeutics to $150 From $105, Keeps Buy Rating - marketscreener.com
Rezpegaldesleukin Shows Sustained Benefit in Moderate-to-Severe Atopic Dermatitis in Phase 2 b trial - Medical Dialogues
Jonathan Zalevsky Sells 180 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock - MarketBeat
Howard Robin Sells 423 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock - MarketBeat
What is Nektar Therapeutics’s valuation compared to sectorJuly 2025 Highlights & Weekly Stock Breakout Alerts - mfd.ru
Persistent Asset Partners Ltd Takes $983,000 Position in Nektar Therapeutics $NKTR - MarketBeat
Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight - StreetInsider
Nektar Therapeutics stock pops on $300M equity offering - MSN
UCSF, Nektar team to test potential of antibody therapy for MS - Multiple Sclerosis News Today
Which Is a Better Investment, Liquidia Corporation or Nektar Therapeutics Stock? - AAII.com
Which Is a Better Investment, Amneal Pharmaceuticals, Inc. or Nektar Therapeutics Stock? - AAII
Nektar Therapeutics: Unique MOA Translates To Stellar AD Maintenance Data, Strong Buy - Seeking Alpha
Nektar Therapeutics and UCSF explore TNFR2 agonism in MS - BioWorld MedTech
Nektar Therapeutics (NASDAQ:NKTR) Reaches New 12-Month HighShould You Buy? - MarketBeat
45,042 Shares in Nektar Therapeutics $NKTR Bought by Readystate Asset Management LP - MarketBeat
Nektar Therapeutics Announces Research Collaboration with University of California, San Francisco - marketscreener.com
StockWatch: Nektar’s Rezpeg Sparks a Sweet “Comeback Story” - Genetic Engineering and Biotechnology News
Nektar Therapeutics Azioni (NKTR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
6.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):